SEC Form 4 · accession 0001790340-26-000078
Immuneering Corp · IMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Benjamin J. Zeskind
Officer — PRESIDENT AND CEO · Director
Period of report
Jun 23, 2026
Accepted (ET)
Jun 24, 2026 · 4:11 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001790340
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF1 | Jun 23, 2026 | P | 2,400 | $4.5617 | A | 2,315,252 | D | |
| Class A Common StockF2 | holding | — | — | — | 894,927 | I | See Foonote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.55 to $4.59. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.
- F2Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee.